- Home
- RGNX vs ORIC Comparison
RGNX vs ORIC Comparison
Compare RGNX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- ORIC
- Stock Information
- Founded
- RGNX 2008
- ORIC 2014
- Country
- RGNX United States
- ORIC United States
- Employees
- RGNX N/A
- ORIC N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- RGNX Health Care
- ORIC Health Care
- Exchange
- RGNX Nasdaq
- ORIC Nasdaq
- Market Cap
- RGNX 424.8M
- ORIC 362.9M
- IPO Year
- RGNX 2015
- ORIC 2020
- Fundamental
- Price
- RGNX $8.70
- ORIC $10.82
- Analyst Decision
- RGNX Strong Buy
- ORIC Strong Buy
- Analyst Count
- RGNX 8
- ORIC 9
- Target Price
- RGNX $31.75
- ORIC $18.29
- AVG Volume (30 Days)
- RGNX 788.1K
- ORIC 936.6K
- Earning Date
- RGNX 07-31-2025
- ORIC 08-11-2025
- Dividend Yield
- RGNX N/A
- ORIC N/A
- EPS Growth
- RGNX N/A
- ORIC N/A
- EPS
- RGNX N/A
- ORIC N/A
- Revenue
- RGNX $156,718,000.00
- ORIC N/A
- Revenue This Year
- RGNX $327.08
- ORIC N/A
- Revenue Next Year
- RGNX N/A
- ORIC N/A
- P/E Ratio
- RGNX N/A
- ORIC N/A
- Revenue Growth
- RGNX 80.70
- ORIC N/A
- 52 Week Low
- RGNX $5.04
- ORIC $3.90
- 52 Week High
- RGNX $15.36
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- RGNX 48.91
- ORIC 66.82
- Support Level
- RGNX $8.39
- ORIC $10.42
- Resistance Level
- RGNX $9.27
- ORIC $11.50
- Average True Range (ATR)
- RGNX 0.53
- ORIC 0.62
- MACD
- RGNX 0.03
- ORIC -0.03
- Stochastic Oscillator
- RGNX 59.86
- ORIC 83.30
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.